Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
ST. PETERSBURG, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Water Tower Research ( www.watertowerresearch.com ) has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”. The report can be accessed here A leader in novel neuropsychiatric therapeutics. Stewarded by a highly experienced and accomplished executive management team with deep and broad pharma industry knowledge, Cybin has been positioned as the most advanced developer of innovative neuropsychiatry treatments targeting hard-to-treat mental health disorders that affect large swathes of the global population, including major depressive disorder (MDD) and generalized anxiety disorder (GAD). Cybin can also claim to have the most extensive IP real estate among its peer group. Rapid advancement of lead pipeline candidates. Cybin's primary focus is on its two lead pipeline candidates: (1) CYB003, a deuterated psilocin-based treatment for MDD; and (2) CYB00
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitBusiness Wire
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- Cybin Provides Corporate Update on Upcoming Clinical MilestonesBusiness Wire
- 'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]Seeking Alpha
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/20/24 - Form 6-K
- CYBN's page on the SEC website